FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:LANCL2-TTC3

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: LANCL2-TTC3
FusionPDB ID: 44030
FusionGDB2.0 ID: 44030
HgeneTgene
Gene symbol

LANCL2

TTC3

Gene ID

55915

7267

Gene nameLanC like 2tetratricopeptide repeat domain 3
SynonymsGPR69B|TASPDCRR1|RNF105|TPRDIII
Cytomap

7p11.2

21q22.13

Type of geneprotein-codingprotein-coding
DescriptionlanC-like protein 2G protein-coupled receptor 69BLanC (bacterial lantibiotic synthetase component C)-like 2LanC lantibiotic synthetase component C-like 2testis-specific adriamycin sensitivity proteinE3 ubiquitin-protein ligase TTC3RING finger protein 105RING-type E3 ubiquitin transferase TTC3TPR repeat protein 3TPR repeat protein Dtetratricopeptide repeat protein 3
Modification date2020031320200320
UniProtAcc

Q9NS86

Main function of 5'-partner protein: FUNCTION: Necessary for abscisic acid (ABA) binding on the cell membrane and activation of the ABA signaling pathway in granulocytes. {ECO:0000269|PubMed:19667068}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000254770, ENST00000486376, 
ENST00000479930, ENST00000399010, 
ENST00000540756, ENST00000354749, 
ENST00000355666, ENST00000399017, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score9 X 5 X 5=22519 X 18 X 9=3078
# samples 1024
** MAII scorelog2(10/225*10)=-1.16992500144231
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(24/3078*10)=-3.68088692071969
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: LANCL2 [Title/Abstract] AND TTC3 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: LANCL2 [Title/Abstract] AND TTC3 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)LANCL2(55433922)-TTC3(38544897), # samples:1
Anticipated loss of major functional domain due to fusion event.LANCL2-TTC3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
LANCL2-TTC3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
LANCL2-TTC3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
LANCL2-TTC3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneLANCL2

GO:0009789

positive regulation of abscisic acid-activated signaling pathway

19667068

HgeneLANCL2

GO:0045892

negative regulation of transcription, DNA-templated

12566319

TgeneTTC3

GO:0006511

ubiquitin-dependent protein catabolic process

20059950

TgeneTTC3

GO:0070936

protein K48-linked ubiquitination

20059950



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:55433922/chr21:38544897)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across LANCL2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across TTC3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000254770LANCL2chr755433922+ENST00000355666TTC3chr2138544897+39227825452392615
ENST00000254770LANCL2chr755433922+ENST00000399017TTC3chr2138544897+39317825452392615
ENST00000254770LANCL2chr755433922+ENST00000354749TTC3chr2138544897+39317825452392615

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000254770ENST00000355666LANCL2chr755433922+TTC3chr2138544897+0.0003419530.9996581
ENST00000254770ENST00000399017LANCL2chr755433922+TTC3chr2138544897+0.0003456920.9996543
ENST00000254770ENST00000354749LANCL2chr755433922+TTC3chr2138544897+0.0003456920.9996543

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for LANCL2-TTC3

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
LANCL2chr755433922TTC3chr213854489778279TDEPGLPFHQDGKGEISRIEKEHQVL

Top

Potential FusionNeoAntigen Information of LANCL2-TTC3 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
LANCL2-TTC3_55433922_38544897.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
LANCL2-TTC3chr755433922chr2138544897782HLA-B39:01FHQDGKGEI0.99680.8432716
LANCL2-TTC3chr755433922chr2138544897782HLA-B38:01FHQDGKGEI0.9940.9496716
LANCL2-TTC3chr755433922chr2138544897782HLA-B38:02FHQDGKGEI0.99350.9436716
LANCL2-TTC3chr755433922chr2138544897782HLA-B39:06FHQDGKGEI0.9920.8025716
LANCL2-TTC3chr755433922chr2138544897782HLA-B39:24FHQDGKGEI0.98940.5011716
LANCL2-TTC3chr755433922chr2138544897782HLA-B15:37FHQDGKGEI0.51720.563716
LANCL2-TTC3chr755433922chr2138544897782HLA-B39:09FHQDGKGEI0.99650.6012716
LANCL2-TTC3chr755433922chr2138544897782HLA-B39:12FHQDGKGEI0.99560.8543716
LANCL2-TTC3chr755433922chr2138544897782HLA-B39:05FHQDGKGEI0.99350.8337716
LANCL2-TTC3chr755433922chr2138544897782HLA-B14:03FHQDGKGEI0.35890.6914716
LANCL2-TTC3chr755433922chr2138544897782HLA-B39:31FHQDGKGEI0.99690.8485716
LANCL2-TTC3chr755433922chr2138544897782HLA-B38:05FHQDGKGEI0.9940.9496716
LANCL2-TTC3chr755433922chr2138544897782HLA-B15:09FHQDGKGEI0.96890.8365716
LANCL2-TTC3chr755433922chr2138544897782HLA-B39:11FHQDGKGEI0.88020.8372716
LANCL2-TTC3chr755433922chr2138544897782HLA-C07:04FHQDGKGEI0.45280.9087716

Top

Potential FusionNeoAntigen Information of LANCL2-TTC3 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
LANCL2-TTC3_55433922_38544897.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
LANCL2-TTC3chr755433922chr2138544897782DRB1-0305GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-0305PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-0305EPGLPFHQDGKGEIS217
LANCL2-TTC3chr755433922chr2138544897782DRB1-0305LPFHQDGKGEISRIE520
LANCL2-TTC3chr755433922chr2138544897782DRB1-0338GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-0338PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-0338EPGLPFHQDGKGEIS217
LANCL2-TTC3chr755433922chr2138544897782DRB1-0340GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-0340PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-0340EPGLPFHQDGKGEIS217
LANCL2-TTC3chr755433922chr2138544897782DRB1-0340LPFHQDGKGEISRIE520
LANCL2-TTC3chr755433922chr2138544897782DRB1-0466PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-0466GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-0804GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-0806GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-0820GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-0831GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-0831DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1104GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1104DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1106GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1106DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1113GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1118GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1118DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1125GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1134GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1134DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1135GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1135DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1138GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1138DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1141GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1142GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1142DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1143GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1143DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1144GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1144DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1146GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1146DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1147GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1147DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1150GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1150DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1153GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-1153PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-1154GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1154DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1156GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1156DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1157GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1157DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1158GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1158DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1159GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1160GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1160DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1177GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1177DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1178GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1178DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1179GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-1179PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-1183GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1183DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1184GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1184DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1188GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1188DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1192GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1306GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1306DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1309GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1309DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-13101PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-13101GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-1310PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-1310GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-1311GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1311DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1318GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1332GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1333GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-1333PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-1337GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-1337PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-1342GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1342DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1344GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1344DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1348GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1358GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1381GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1381DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1389GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1389DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1394GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1394DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1406GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1406DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1407GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-1407PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-1409GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-1409PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-1411GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1412GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1415GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1417GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1417DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1419GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-1419PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-1420GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1420DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1421GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1421DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1429GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1429DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1433GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1433DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1434GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1437GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1437DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1449GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-1449PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-1451GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-1465GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1473GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1473DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1474GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1474DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1478GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1480GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1480DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1481GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1483GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1483DGKGEISRIEKEHQV1025
LANCL2-TTC3chr755433922chr2138544897782DRB1-1484GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB1-1493GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB1-1493PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB1-1495GKGEISRIEKEHQVL1126
LANCL2-TTC3chr755433922chr2138544897782DRB3-0114GLPFHQDGKGEISRI419
LANCL2-TTC3chr755433922chr2138544897782DRB3-0114PGLPFHQDGKGEISR318
LANCL2-TTC3chr755433922chr2138544897782DRB3-0114EPGLPFHQDGKGEIS217

Top

Fusion breakpoint peptide structures of LANCL2-TTC3

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6615PFHQDGKGEISRIELANCL2TTC3chr755433922chr2138544897782

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of LANCL2-TTC3

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6615PFHQDGKGEISRIE-7.28656-7.39996
HLA-B14:023BVN6615PFHQDGKGEISRIE-5.68504-6.72034
HLA-B52:013W396615PFHQDGKGEISRIE-7.45611-7.56951
HLA-B52:013W396615PFHQDGKGEISRIE-4.23128-5.26658
HLA-A24:025HGA6615PFHQDGKGEISRIE-5.90012-6.01352
HLA-A24:025HGA6615PFHQDGKGEISRIE-5.24438-6.27968
HLA-B44:053DX86615PFHQDGKGEISRIE-6.74318-6.85658
HLA-B44:053DX86615PFHQDGKGEISRIE-3.24185-4.27715
HLA-A02:016TDR6615PFHQDGKGEISRIE-7.43467-7.54807

Top

Vaccine Design for the FusionNeoAntigens of LANCL2-TTC3

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
LANCL2-TTC3chr755433922chr2138544897716FHQDGKGEITTTCATCAGGACGGGAAGGGGGAAATT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
LANCL2-TTC3chr755433922chr21385448971025DGKGEISRIEKEHQVGACGGGAAGGGGGAAATTTCACGGATTGAAAAGGAGCACCAAGTA
LANCL2-TTC3chr755433922chr21385448971126GKGEISRIEKEHQVLGGGAAGGGGGAAATTTCACGGATTGAAAAGGAGCACCAAGTATTA
LANCL2-TTC3chr755433922chr2138544897217EPGLPFHQDGKGEISGAGCCCGGCCTCCCTTTTCATCAGGACGGGAAGGGGGAAATTTCA
LANCL2-TTC3chr755433922chr2138544897318PGLPFHQDGKGEISRCCCGGCCTCCCTTTTCATCAGGACGGGAAGGGGGAAATTTCACGG
LANCL2-TTC3chr755433922chr2138544897419GLPFHQDGKGEISRIGGCCTCCCTTTTCATCAGGACGGGAAGGGGGAAATTTCACGGATT
LANCL2-TTC3chr755433922chr2138544897520LPFHQDGKGEISRIECTCCCTTTTCATCAGGACGGGAAGGGGGAAATTTCACGGATTGAA

Top

Information of the samples that have these potential fusion neoantigens of LANCL2-TTC3

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
LGGLANCL2-TTC3chr755433922ENST00000254770chr2138544897ENST00000354749TCGA-E1-A7YQ-01A

Top

Potential target of CAR-T therapy development for LANCL2-TTC3

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to LANCL2-TTC3

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to LANCL2-TTC3

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource